Karan R. Kumar

Karan R. Kumar

Auto-generated profile, based on publicly available information

Karan R. Kumar

Department of Pediatrics, Duke University, Durham, North Carolina, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2019 in Journal of Perinatology
Verified
Journal Article
Closed access
PDF file
MPMihai Puia-Dumitrescu
Mihai Puia-Dumitrescu
DTDavid T. Tanaka
David T. Tanaka
TSTracy G. Spears
Tracy G. Spears
CDCecil J. Daniel
Cecil J. Daniel
KKKaran R. Kumar
Karan R. Kumar
PSP. Brian Smith
P. Brian Smith

18 May 2022 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
JGJacqueline G. Gerhart
Jacqueline G. Gerhart
FCFernando O. Carreño
Fernando O. Carreño
MLMatthew Shane Loop
Matthew Shane Loop
CLCraig R. Lee
Craig R. Lee
AEAndrea Edginton
Andrea Edginton
TCthe Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee
the Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee
Dosing guidance for children with obesity is often unknown despite the fact that nearly 20% of US children are classified as obese. Enoxaparin, a commonly prescribed low‐molecular‐weight heparin, is dosed based on body weight irrespective of obesity status to achieve maximum concentration within a narrow therapeutic or prophylactic target range. However, whether children with and without obesity experience equivalent enoxaparin exposure remains unclear. To address this clinical question, 2,825 anti–activated factor X (anti‐Xa) surrogate concentrations were collected from the electronic health records of 596 children, including those with obesity. Using linear mixed‐effects regression models, we observed that 4‐hour anti‐Xa concentrations were statistically significantly different in children with and without obesity, even for children with the same absolute dose (P = 0.004). To further mechanistically explore obesity‐associated differences in anti‐Xa concentration, a pediatric physiologically‐based pharmacokinetic (PBPK) model was developed in adults, and then scaled to children with and without obesity. This PBPK model incorporated binding of enoxaparin to antithrombin to form anti‐Xa and elimination via heparinase‐mediated metabolism and glomerular filtration. Following scaling, the PBPK model predicted real‐world pediatric concentrations well, with an average fold error (standard deviation of the fold error) of 0.82 (0.23) and 0.87 (0.26) in children with and without obesity, respectively. PBPK model simulations revealed that children with obesity have at most 20% higher 4‐hour anti‐Xa concentrations under recommended, total body weight–based dosing compared to children without obesity owing to reduced weight‐normalized clearance. Enoxaparin exposure was better matched across age groups and obesity status using fat‐free mass weight‐based dosing.

1 November 2018 in The Journal of Pediatrics
Verified
Journal Article
Closed access
KKKaran R. Kumar
Karan R. Kumar
DCDavid A. Clark
David A. Clark
EKEvan M. Kim
Evan M. Kim
JPJasmine D. Perry
Jasmine D. Perry
KWKaylyn Wright
Kaylyn Wright
CHChristoph P. Hornik
Christoph P. Hornik

1 January 2023 in Congenital Heart Disease
Verified
Journal Article
Open access
PDF file
HFHenry P. Foote
Henry P. Foote
HWHuali Wu
Huali Wu
SBStephen J. Balevic
Stephen J. Balevic
ETElizabeth J. Thompson
Elizabeth J. Thompson
KHKevin D. Hill
Kevin D. Hill
KKKaran R. Kumar
Karan R. Kumar
Background: Infants undergoing cardiac surgery with cardiopulmonary bypass (CPB) frequently receive intra-operative methylprednisolone (MP) to suppress CPB-related inflammation; however, the optimal dosing strategy and efficacy of MP remain unclear. Methods: We retrospectively analyzed all infants under 90 days-old who received intra-operative MP for cardiac surgery with CPB from 2014–2017 at our institution. We combined real-world dosing data from the electronic health record (EHR) and two previously developed population pharmacokinetic/pharmacodynamic models to simulate peak concentration (Cmax) and area under the concentration-time curve for 24 h (AUC24) for MP and the inflammatory cytokines interleukin-6 (IL-6) and interleukin-10 (IL-10). We evaluated the relationships between post-operative, safety, and other clinical outcomes obtained from the EHR with each predicted exposure using non-parametric tests. Results: A total of 142 infants with median post-natal age 8 (interquartile range [IQR]: 5, 37) days received a total dose of 30 (19, 49) mg/kg of MP. Twelve (8%) died, 37 (26%) met the composite post-operative outcome, 114 (80%) met the composite safety outcome, and 23 (16%) had a major complication. Predicted median Cmax and AUC24 IL-6 exposure was significantly higher for infants meeting the composite post-operative outcome and those with major complications. Predicted median Cmax and AUC24 MP exposure was significantly higher for infants requiring insulin. No exposure was associated with death or other safety outcomes. Conclusions: Pro-inflammatory IL-6, but not MP exposure, was associated with post-operative organ dysfunction, suggesting current MP dosing may not adequately suppress IL-6 or increase IL-10 to impact clinical outcomes. Prospective study will be required to define the optimal exposure-efficacy and exposure-safety profiles in these infants.

6 September 2019 in Journal of Perinatology
Verified
Journal Article
Closed access
PDF file
SGSamantha Gonski
Samantha Gonski
SHSusan R. Hupp
Susan R. Hupp
CCC. Michael Cotten
C. Michael Cotten
RCReese H. Clark
Reese H. Clark
MLMatthew Laughon
Matthew Laughon
RGRachel G. Greenberg
Rachel G. Greenberg

1 December 2023 in Journal of the Pediatric Infectious Diseases Society
Verified
Journal Article
Closed access
PDF file
KKKaran R Kumar
Karan R Kumar
SSSonam J Shah
Sonam J Shah
RFRawan M Fayyad
Rawan M Fayyad
TTToby M Turla
Toby M Turla
LOLaura M O’sUllivan
Laura M O’sUllivan
CHChristoph P Hornik
Christoph P Hornik
Background: We examined the association between hypoglycemia and the occurrence of early onset sepsis (EOS) in premature infants admitted to the neonatal intensive care unit (NICU). Methods: We included infants discharged from 358 NICUs between 1997 and 2020 with gestational age <34 weeks, ≥1 culture collected in the first 3 days of life, and ≥1 serum glucose value recorded on the day of or day prior to culture collection. We used multivariable logistic regression and inverse probability weighting (IPW) and constructed models for three definitions of hypoglycemia: American Academy of Pediatrics (AAP), Pediatric Endocrine Society, and a definition based on neurodevelopmental studies. We performed subgroup analysis in EOS episodes caused by Gram-negative and Gram-positive organisms. Results: Of the 62,178 infants and 64,559 cultures that met study inclusion criteria, 739 (1%) cultures were positive. The median (25th, 75th percentile) glucose value was 75 mg/dL (50, 106) on the day of or day prior to a positive culture versus 70 mg/dL (50, 95) on the day of or day prior to a negative culture. We found that hypoglycemia was not associated with the occurrence of EOS for all organisms and Gram-positive organisms, whereas there was a small but significant association between the lower AAP glucose cutoff value and EOS due to Gram-negative organisms (logistic regression: risk difference [RD] 0.24% [95% CI, 0.01-0.47]; IPW: RD 0.22% [95% CI, 0.00-0.43]). Conclusions: Hypoglycemia may be an early marker of EOS, particularly in episodes caused by Gram-negative organisms and when using a stricter definition of hypoglycemia.